NCT05434546View on ClinicalTrials.gov

A Study to Explore the Effect of Sepranolone in Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Tourette SyndromeTourette Syndrome in Adolescence
Interventions
DRUG

Sepranolone

Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.

Trial Locations (2)

2400

Bispebjerg Hospital, Copenhagen

2730

Herlev Hospital, Copenhagen

Sponsors

Lead Sponsor

Asarina Pharma
All Listed Sponsors
lead

Asarina Pharma

INDUSTRY

NCT05434546 - A Study to Explore the Effect of Sepranolone in Tourette Syndrome | Biotech Hunter | Biotech Hunter